

Clinical Policy: Rufinamide (Banzel)

Reference Number: HIM.PA.90

Effective Date: 12/14

Last Review Date: 08/17

Line of Business: Health Insurance Marketplace

[Coding Implications](#)

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Rufinamide (Banzel[®]) is a triazole derivative structurally unrelated to currently marketed antiepileptic drugs (AEDs).

FDA approved indication

Banzel is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in pediatric patients 1 year of age and older, and in adults.

Policy/Criteria

Provider must submit documentation (including office chart notes and lab results) supporting that member has met all approval criteria

I. Initial Approval Criteria

A. Lennox-Gastaut Syndrome (must meet all):

1. Diagnosis of Lennox-Gastaut syndrome (LGS);
2. Prescribed by or in consultation with a neurologist;
3. Failure of two formulary alternatives for LGS (e.g., clonazepam, felbamate, lamotrigine, topiramate) unless all are contraindicated or clinically significant adverse effects are experienced;
4. Dose does not exceed 3200 mg per day.

Approval duration: 12 months

B. Other diagnoses/indications

1. Refer to HIM.PHAR.21 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized)

II. Continued Therapy

A. Lennox-Gastaut Syndrome (must meet all):

1. Currently receiving medication via Centene benefit, or documentation supports that member is currently receiving Banzel for Lennox-Gastaut syndrome and has received this medication for at least 30 days;
2. Documentation of positive response to therapy;
3. If request is for a dose increase, new dose does not exceed 3200 mg per day.

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2):

1. Currently receiving medication via health plan benefit and documentation supports positive response to therapy.

Approval duration: Duration of request or 12 months (whichever is less); or

CLINICAL POLICY

Rufinamide

2. Refer to HIM.PHAR.21 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized)

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy – HIM.PHAR.21 or evidence of coverage documents

IV. Appendices/General Information

Appendix A: Abbreviation Key

FDA: Food and Drug Administration

LGS: Lennox-Gastaut syndrome

V. References

1. Banzel Prescribing Information. Woodcliff Lake, NJ: Eisai Inc.; June 2015. Available at: <https://www.banzel.com/areas/banzel/pdfs/BanzelPI.pdf>. Accessed January 19, 2017.
2. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy. Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. *Neurology*. 2004 Apr 27;62(8):1261-73.
3. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; Accessed January 19, 2017. Available at: <http://www.clinicalpharmacology-ip.com>
4. Micromedex® Healthcare Series [Internet database]. Greenwood Village, Colo: Thomson Healthcare. Updated periodically. Accessed January 19, 2017.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Reformatted guideline to new format. Added Workflow reference document.	12/15	12/15
Modified requirement related to formulary trial to include trial and failure of two formulary alternatives. Removed workflow document. Updated references to reflect current literature search.	08/16	08/16
Converted to new template. Added prescriber specialty; removed continuity of care from initial approval section and incorporated it in the continuation criteria; added max dose. Updated references.	04/17	08/17

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical

CLINICAL POLICY

Rufinamide

policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note: For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

CLINICAL POLICY

Rufinamide

©2017 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.